Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Weekly Oral GS-3242 + Lenacapavir in Virologically Suppressed People With HIV-1
NCT07841990Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of GS-3242 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Oct 2026; status: recruiting.
02
Drugs
GS-3242
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07841990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841990.